An analyst called the data, on ZGN-1061, encouraging in a relatively small study but added that more preclinical data will be needed to give a clearer picture of the way forward for the drug.
The company's shares were down more than 40 percent in midday trading as the FDA placed a clinical hold on ZGN-1061, the second such hold the company has experienced in three years.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Update below Drug developer Zafgen priced its IPO at the upper end of its projected share price range ($16) on the evening before its public debut on the Nasdaq. It reflects confidence in the company’s unconventional injectible drug to treat severe obesity. It’s seeking to raise $96 million to push its drug alternative to costly […]